How to Choose a Local Agent for Medical Device Registration in Thailand

Direct answer: Choosing a local agent for medical device registration in Thailand should begin with regulatory capability rather than commercial convenience. Before appointing a partner, confirm the product classification and applicable TFDA pathway, then assess whether the candidate agent can act as the local representative or authorised representative with clearly defined responsibility for regulatory communication, certificate control, change notifications, renewal maintenance and post-market event handling. Existing NMPA documentation can serve as a baseline, but it normally must be adapted for language, format, labelling and evidence-chain requirements under Thai TFDA rules.

Thailand registration typically requires confirmation of product classification and the applicable submission route before preparing technical files, labels and instructions for use, quality management system evidence, authorisation documents and local representative information. For Chinese medical device manufacturers, the more reliable approach is to complete a product classification and documentation gap assessment first, and only then decide whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Thailand registration usually affects technical documentation, the authorised representative, importer coordination, label language, quality management system evidence and subsequent change maintenance at the same time. If the project is driven only by a document checklist, deficiencies and rework are likely to arise in model coverage, evidence-chain consistency, label claims and control over certificates. AIMEILI recommends positioning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets rather than rebuilding documentation country by country.

Manufacturers should also make project-based judgements by combining the latest requirements of the target regulatory authority, the existing technical file base, the product risk class and the launch plan, rather than preparing mechanically against a document list.

Published: 10 July 2026, 12:23  |  Updated: 10 July 2026, 12:23

Key Summary

Medical device registration in Thailand generally requires confirming the product classification and applicable pathway first, then preparing technical documentation, labels and instructions for use, quality management system evidence, authorisation documents and local representative information. Existing NMPA documentation can be used as a baseline, but it usually needs to be adapted to Thai TFDA requirements in terms of language, format, labelling and evidence chain.

For Chinese medical device manufacturers, the more prudent approach is to carry out a product classification and documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Thailand registration normally affects technical documentation, the authorised representative, importer coordination, label language, quality management system evidence and subsequent change maintenance at the same time. If a project proceeds only on the basis of which documents must be submitted, deficiencies or rework is likely in model coverage, evidence-chain consistency, label claims and control over certificates. AIMEILI recommends planning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation across markets instead of redoing documentation on a temporary basis for each country.

Manufacturers should also make project-based judgements based on the latest requirements of the target regulatory authority, the existing technical file base, the product risk class and the launch plan, avoiding mechanical preparation against a document list alone.

Applicable Scenarios and Core Questions

Companies searching for guidance on how to choose a local agent for medical device registration in Thailand are usually not looking for a conceptual explanation. What they need to determine is whether their existing documentation can support a Thai submission, whether a local agent or authorised representative is required, why timelines become extended, and which issues may affect the launch plan. Behind this question there are usually several linked considerations: product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibilities.

If a manufacturer plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the procedure of a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality management system evidence, performance verification, clinical evidence and labels and instructions for use, and then localise them according to each country's regulatory requirements.

Registration Decision Logic

Manufacturers should first confirm the intended use, mechanism of action, use scenario, method and duration of body contact, whether the device is sterile, whether it is active, and whether it contains software or has IVD characteristics. On that basis, the risk class and submission pathway can be determined. If the pathway is judged incorrectly, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For a Thailand project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are handled vaguely in a commercial contract only, market control can be seriously affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality management system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, authorisation documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the scope of application of clinical evidence, the conclusions of risk management, label warnings and the information in the registration application form must support one another. What the regulatory authority assesses is whether the device is safe, effective and traceable for the intended use, not whether the manufacturer has uploaded a large number of files.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Translating NMPA documentation directly and submitting it without reorganising the evidence according to the Thai pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on the basis of a sales partnership, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and registration documentation, leading to deficiency notices or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, resulting in repeated preparation for each country and inflated cost and timelines.

Manufacturer Preparation Checklist

Before starting a project, manufacturers are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorised representative.
• Establish a target-country gap assessment table identifying what needs additional testing, translation, notarisation or supplementary declarations.

AIMEILI's View

AIMEILI recommends that manufacturers do not treat Thailand registration as a one-off document submission, but manage it as an overseas market access programme. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable and more conducive to subsequent changes and renewals than supplementing documentation on a country-by-country basis.

From a project management perspective, three matters should be controlled in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the boundaries of regulatory responsibility of the local partner. If these three items are unclear, a project may still encounter repeated rounds of deficiencies, agent communication and post-market maintenance issues even when the documentation appears extensive.

Frequently Asked Questions

Can domestic (NMPA) documentation be used directly for Thai registration?

Domestic documentation can serve as a baseline, but it usually cannot be submitted as it stands. Manufacturers need to adjust the documentation structure, language, labelling, authorisation documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after the target markets and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adaptation and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in registration communication, changes, renewal and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a registration review perspective, quality management system documentation is not an isolated certificate. Regulatory authorities generally examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the products being registered, or if the manufacturing site, model and specification, or version of the instructions for use is inconsistent with the test report, a manufacturer may be asked for supplementary clarification even when a large volume of documentation has been prepared.

Before submission, manufacturers should build an evidence consistency checklist mapping product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version, and quality management system certificate item by item. This step appears basic, but it can significantly reduce the probability of deficiency notices, particularly for projects submitting for several GHWP member states or several product families at the same time.

Localisation and Agent Responsibilities

Thailand registration projects usually involve arrangements for a local agent, authorised representative, importer or registration holder. Manufacturers need to confirm in advance whether the local partner is only responsible for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use and authorisation documents cannot simply be translated either. Manufacturers should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation is converting reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documentation.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean the compliance work is finished. Manufacturers also need to maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort at the approval stage but neglect post-market maintenance; as a result, when a manufacturing site change, model extension, instructions for use update or agent replacement occurs, the certificate and market sales can become disconnected.

AIMEILI recommends managing this question within an annual international registration plan: first clarify target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency in an individual country, but also the development of a replicable overseas compliance capability that reduces the cost of starting documentation from scratch each time a new market is entered.

Further Reading

• Previous: How Should an ISO 13485 Certificate Be Used for Medical Device Registration in Thailand?
• Next: How Are Authorised Representative Responsibilities Divided for Medical Device Registration in Thailand?
• Recommended reading: How Should Documentation Be Prepared for Medical Device Registration in Malaysia?
• Recommended reading: How Is Product Classification Determined for Medical Device Registration in Malaysia?
• Recommended reading: How Should the Technical File Be Organised for Medical Device Registration in Malaysia?
• Recommended reading: How Should Labels and Instructions for Use Be Localised for Medical Device Registration in Malaysia?
• Recommended reading: How Should Clinical Evaluation Documentation Be Prepared for Medical Device Registration in Malaysia?
• Recommended reading: Can Test Reports Be Reused for Medical Device Registration in Malaysia?

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team  |  Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.